Click here for slides on this topic


Renal

Pertaining to the kidney.


The following content matched the glossary term: Renal

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Changes in diabetes-related complications in the United States, 1990–2010

Top

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514-1523.

American Diabetes Association (ADA)/American Geriatrics Society (AGS) Guidelines 2012

Top

Diabetes management guidelines for older adults from the American Diabetes Association (ADA)/American Geriatrics Society (AGS) 

Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia

Top

Exclusive! Expert video from Burton E. Sobel, MD, on the debate over intensive vs somewhat less intensive glycemic control in the context of this study. Zhao Y, Campbell CR, Fonseca V, Shi L. Assessing Vascular Disease Risk Associated with Medication-Related Hypoglycemia. Diabetes Care. 2012;35(5):1126-1132. Zhao and colleagues examined the impact of hypoglycemia associated with antihyperglycemic medications on vascular risk among veterans with type 2 diabetes in a retrospective cohort study.

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis

Top

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes: systematic review and meta-analysis. Arch Intern Med. 2012;172(10:761-769

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

Top

The effects of salsalate on glycemic control in patients with type 2 diabetes a randomized trialGoldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE for the TINSAL T2D Study Team. Ann Intern Med. 2010 152 346 357. The Targeting Inflammation Using Salsalate* in Type 2 Diabetes (TINSAL-T2D) trial was a parallel, randomized, placebo-controlled multicenter trial evaluating the safety and efficacy of salsalate in subjects with type 2 diabetes.

Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes

Top

Variation of fasting plasma glucose a predictor of mortality in patients with type 2 diabetes Lin CC, Li CI, Yang SY, Liu CS, Chen CC, Fuh MM, Chen W, Li TC. Am J Med. 2012 125(4) 416.e9 18.  The aim of this study was to examine whether time-dependent annual fasting plasma glucose (FPG) variation, as represented by coefficient of variation (CV), can predict mortality in subsequent all-cause, expanded, and nonexpanded cardiovascular disease-related mortality independent of mean FPG, renal function, mean hemoglobin A(1)C (HbA(1C)), HbA(1C) variation, and other risk factors in patients with type 2 diabetes.

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

1 2 3 4 5 6 7 8 Next 

Slide Library Results

Search Results for: Renal Slides Found: 74
Rates of End-Stage Renal Disease in Diabetes Four Ethnic Groups
Adiponectin and CRP Levels in Healthy Obese Women
HF in Women >=65 Yr Old Strongly Associated With Preserved LVSF
Exenatide: Clinical Pharmacology
ALLHAT: Clinical Outcomes in Antihypertensive Treatments
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
RENAAL: Impact of Losartan in Chronic Kidney Disease
RENAAL: Risk Reduction With Losartan--Design
Diabetes: The Most Common Cause of ESRD
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHF in Patients With Type 2 Diabetes
Hypoglycemia Risk Factors in Elderly Patients With Type 2 Diabetes
NICE-SUGAR: Study Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
TINSAL-T2D Trial: Design
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
TINSAL-T2D Trial: Baseline Characteristics
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Considerations for Individualizing Treatment (2 of 2)
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
ADVANCE Post-hoc Analysis: Low HDL-C and Microvascular Event Risk
ADVANCE Post-hoc Analysis: HDL-C Predicts Microvascular Risk
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Clinical CV Event
nbESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Nephropathy
ESH/ESC Hypertension Guidelines: Treatment for Patients With Resistant Hypertension
ESH/ESC Hypertension Guidelines: Treatment of Risk Factors Associated With Hypertension
Canagliflozin: Renal Considerations
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
ALTITUDE: Increased Hyperkalemia, Renal Impairment with Aliskiren
ONTARGET: Significantly Increased Risk of Renal Impairment with Combination Therapy
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
GLP-1 Receptor Agonists: Dosage Adjustment by Degree of Renal Impairment
Metformin: Renal Considerations
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
AleCardio: Aleglitazar Safety Vs Placebo
US Adults Diagnosed Diabetes | Diabetes Slides | NDEI
Diabetes Complications Decreased in US | Diabetes Slides | NDEI
Diabetes Complications in US Diagnosed or Undiagnosed | NDEI
Diabetes Complications Relative Risks US Adults | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Treatment Management | NDEI
IDF 2012 Type 2 Diabetes Guidelines Blood Pressure Targets | NDEI
IDF Type 2 Diabetes Guidelines Cardiovascular Risk | NDEI
IDF Type 2 Diabetes Guidelines Kidney Disease | NDEI
IDF Type 2 Diabetes Treatment Guidelines Older Adults Elderly | NDEI
IDF Type 2 Diabetes Guidelines In-Patient Critically Ill | NDEI
Canola Oil Glycemia A1C Type 2 Diabetes | NDEI
Canola Oil Glycemic Control CVD Type 2 Diabetes | NDEI
Canola Oil Study Glycemic Control A1C Type 2 Diabetes | NDEI
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
JNC 8 Guidelines Treatment Hypertension CKD PPT | NDEI
Diabetes Pregnancy Guidelines Preconception Hypertension | NDEI
Diabetes Pregnancy Guidelines Renal Nephropathy | NDEI
SGLT2 Inhibitors Type 2 Diabetes Treatment Slides | NDEI
SGLT Glucose Homeostasis Diabetes Education Slides | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission A1C Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Diabetes Medication | NDEI
Reports of Acute Pancreatitis Type 2 Diabetes Drugs | NDEI
SGLT2 Dapagliflozin + Insulin Type 1 Diabetes Treatment Slide | NDEI
SBP Reduction Microvascular Outcomes in Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Nephropathy Management Microvascular | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
Kidney Disease in Type 2 Diabetes for CVD Prevention PPT | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Managing Diabetic Kidney Disease ADA Guidelines 2016 | NDEI PPT
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI
Liraglutide Reduces Microvascular Events LEADER CVOT Diabetes PPT | NDEI
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI